Á lódáil...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Public Library of Science (PLoS)
2018-01-01
|
| Sraith: | PLoS ONE |
| Rochtain Ar Líne: | http://europepmc.org/articles/PMC5976165?pdf=render |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|